EDIT vs ROL
Editas Medicine Inc (EDIT) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
EDIT currently screens at market cap $375.2M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the EDIT and ROL stock pages for the full models.
Not investment advice.